Signal
4 articles covering "cancer immunotherapy"
Two companion trials published in Nature Medicine show oral FMT capsules raised immunotherapy response rates to 80% in lung cancer and 75% in melanoma, while reducing toxic side effects in kidney cancer.
A two-particle gene-editing system published in Nature creates functional CAR-T cells in vivo, eliminating the costly weeks-long manufacturing process and clearing leukemia, myeloma, and solid tumors in preclinical models.
The SWOG S2419 BioFront study is the first large-scale randomized trial testing whether a daily oral bacterial supplement can boost immunotherapy outcomes in advanced kidney cancer.
A Cambridge-led study identifies CAG-170 bacteria as a global marker of gut health, Siolta Therapeutics reports a 64 percent reduction in infant atopic dermatitis risk, and UF Health isolates a bacterial metabolite that doubles lung cancer immunotherapy response in mice.